Triple
T11074425
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CD20 protein |
E261827
|
entity |
| Predicate | targetOf |
P860
|
FINISHED |
| Object | ofatumumab (autoimmune indications) |
E854986
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ofatumumab (autoimmune indications) | Statement: [CD20 protein, targetOf, ofatumumab (autoimmune indications)]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ofatumumab (autoimmune indications) Context triple: [CD20 protein, targetOf, ofatumumab (autoimmune indications)]
-
A.
Ofatumumab
chosen
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
D.
isatuximab
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
-
E.
mosunetuzumab (bispecific antibody component)
Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6aa9983c08190b0ef61603b69feac |
completed | April 8, 2026, 7:20 p.m. |
| NER | Named-entity recognition | batch_69d7994e32fc8190a6591d9e82b68f75 |
completed | April 9, 2026, 12:19 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69e3e76a49fc8190945f4770bf808b43 |
completed | April 18, 2026, 8:19 p.m. |
Created at: April 8, 2026, 9:26 p.m.